VectorY CEO Sander van Deventer (L) and Forbion partner Wouter Joustra

Neu­rode­gen­er­a­tive dis­ease-fo­cused Vec­to­rY nabs $138M to bring ALS vec­tor­ized an­ti­body to clin­ic

Seed­ed by Eu­ro­pean VC firm For­bion in 2021, vec­tor­ized an­ti­body start­up Vec­to­rY has an­oth­er $138 mil­lion to work with in a Se­ries A co-led once …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.